Other News

Philips’ response to updated FDA letter to healthcare providers on paclitaxel devices to treat peripheral artery disease

Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its response to the U.S. Food and Drug Administration’s (FDA) Letter to Health Care Providers regarding treatment of peripheral artery disease (PAD) in the superficial femoropopliteal artery (SFA) with paclitaxel-coated devices.    Importantly, the FDA recommendation continues […]

Concept Medical Inc. Granted 2nd ‘Breakthrough Device Designation’ From the FDA for Its MagicTouch PTA Sirolimus Coated Balloon, for the Treatment of Peripheral Artery Disease (PAD) in Below-the-Knee (BTK) Indication

Concept Medical Inc. (CMI) has been granted “Breakthrough Device Designation” from the U.S. Food and Drug Administration (FDA) for MagicTouch PTA (Percutaneous Transluminal Angioplasty), its Sirolimus drug-coated balloon (DCB) catheter, for the treatment of Peripheral Artery Disease (PAD) in Below-the-Knee (BTK). The first ‘Breakthrough Device Designation’ received by Concept Medical […]

AtriCure Enters Into Definitive Agreement to Acquire SentreHEART

Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12th at 8:30am ET MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that […]

CardioMech Raises $5 Million in Heavily Oversubscribed Financing

OSLO, Norway, Aug. 12, 2019 /PRNewswire/ — CardioMech AS, a privately-held company developing a transcatheter mitral valve repair technology, announced today that it has closed on a convertible note financing of $5 million,significantly oversubscribed. The note included investments from experienced MedTech investors and brings the total amount raised for CardioMech to $7.5 million in 2019. Proceeds from […]

Ancora Heart Enrolls First Patient in European Multi-Center Study of First-of-Its-Kind Investigational Heart Failure Therapy

Study will evaluate a percutaneous therapy designed to improve left ventricular function for patients with systolic heart failure SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the first patient was enrolled in the CorCinch EU study, a European multi-center clinical […]

Bardy Diagnostics™ Selected as One of Six Disruptive MedTech Startups For the HealthTech Arkansas Accelerator Program

SEATTLE, Aug. 9, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that HealthTech Arkansas, a healthcare accelerator and investment fund that connects early-stage healthcare companies with disruptive technologies to Arkansas healthcare providers, has selected BardyDx to participate in the organization’s 2019 accelerator program. BardyDx […]

Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA

PDUFA Date Extension to End of December 2019 Expected Management to Host Conference Call Today at 7:00 p.m. ET BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 08, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that it received notice today from the […]

Endologix Receives IDE Approval for the Nellix Chimney EndoVascular Aneurysm Sealing Protocol

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption (“IDE”) approval from the United States Food and Drug Administration (“FDA”) to commence a new pivotal study to evaluate the safety and effectiveness of the Nellix […]

Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced an agreement naming Boston Scientific Corporation (NYSE: BSX) the exclusive distributor for Endologix products in China. The long-term agreement includes distribution rights to Endologix’s current EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm […]

Caladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update

Confirmatory Phase 3 Study Protocol Finalized for CLBS14 in No-Option Refractory Disabling Angina Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 08, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell […]